ANNEX III, Regulation (EU) 2020/217

In forcesince 1 Aug 2025

Annex VI to Regulation (EC) No 1272/2008 is amended as follows:

(1)

Part 1 is amended as follows:

(a)

in point 1.1.3.1, the following notes V and W are added:

If the substance is to be placed on the market as fibres (with diameter < 3 μm, length > 5 μm and aspect ratio ≥ 3:1) or particles of the substance fulfilling the WHO fibre criteria or as particles with modified surface chemistry, their hazardous properties must be evaluated in accordance with Title II of this Regulation, to assess whether a higher category (Carc. 1B or 1A) and/or additional routes of exposure (oral or dermal) should be applied.’

‘It has been observed that the carcinogenic hazard of this substance arises when respirable dust is inhaled in quantities leading to significant impairment of particle clearance mechanisms in the lung.

This note aims to describe the particular toxicity of the substance; it does not constitute a criterion for classification according to this Regulation.’;

(b)

in point 1.1.3.2, the following note 10 is added:

The classification as a carcinogen by inhalation applies only to mixtures in powder form containing 1 % or more of titanium dioxide which is in the form of or incorporated in particles with aerodynamic diameter ≤ 10 μm.’;

(2)

in Part 3, Table 3 is amended as follows:

(a)

the rows with index numbers 604-083-00-X and 611-159-00-6 are deleted;

(b)

the rows corresponding to index numbers 015-189-00-5, 027-001-00-9, 028-018-00-4, 603-023-00-X, 605-005-00-7, 606-047-00-9, 607-232-00-7, 607-247-00-9, 608-039-00-0, 613-054-00-0, 616-018-00-2 and 648-055-00-5 are replaced by the following rows respectively:

Index No | Chemical name | EC No | CAS No | Classification | Labelling | Specific Conc. Limits, M-factors and ATEs | Notes

Hazard Class and Category Code(s) | Hazard statement Code(s) | Pictogram, Signal Word Code(s) | Hazard statement Code(s) | Suppl. Hazard statement Code(s)

‘015-189-00-5 | phenyl bis(2,4,6-trimethylbenzoyl)-phosphine oxide | 423-340-5 | 162881-26-7 |

Skin Sens. 1A

Aquatic Chronic 4

H317

H413

GHS07

Wng

H317

H413’

‘027-001-00-9 | cobalt | 231-158-0 | 7440-48-4 |

Carc. 1B

Muta. 2

Repr. 1B

Resp. Sens. 1

Skin Sens. 1

Aquatic Chronic 4

H350

H341

H360F

H334

H317

H413

GHS08

Dgr

H350

H341

H360F

H334

H317

H413’

‘028-018-00-4 |

nickel bis(sulfamidate);

nickel sulfamate

237-396-1 | 13770-89-3 |

Carc. 1A

Muta. 2

Repr. 1B

Acute Tox. 4

STOT RE 1

Resp. Sens. 1

Skin Sens. 1

Aquatic Acute 1

Aquatic Chronic 1

H350i

H341

H360D***

H302

H372**

H334

H317

H400

H410

GHS08

GHS07

GHS09

Dgr

H350i

H341

H360D***

H302

H372**

H334

H317

H410

oral: ATE = 853 mg/kg bw (anhydrate)

oral: ATE = 1098 mg/kg bw (tetrahydrate)

STOT RE 1;

H372: C ≥ 1 %

STOT RE 2;

H373: 0,1 % ≤ C < 1 %

Skin Sens. 1;

H317: C ≥ 0,01 %

M = 1’

‘603-023-00-X |

ethylene oxide;

oxirane

200-849-9 | 75-21-8 |

Flam. Gas 1

Press. Gas

Carc. 1B

Muta. 1B

Repr. 1B

Acute Tox. 3

Acute Tox. 3

STOT SE 3

STOT SE 3

STOT RE 1

Skin Corr. 1

Eye Dam. 1

H220

H350

H340

H360Fd

H331

H301

H335

H336

H372 (nervous system)

H314

H318

GHS02

GHS08

GHS06

GHS05

Dgr

H220

H350

H340

H360Fd

H331

H301

H335

H336

H372 (nervous system)

H314

inhalation: ATE = 700ppm (gases)

oral: ATE = 100 mg/kg bw’

U

‘605-005-00-7 |

metaldehyde (ISO);

2,4,6,8-tetramethyl-1,3,5,7-tetraoxacyclooctane

203-600-2 | 108-62-3 |

Flam. Sol. 2

Repr. 2

Acute Tox. 3

Aquatic Chronic 3

H228

H361f

H301

H412

GHS02

GHS08

GHS06

Dgr

H228

H361f

H301

H412

oral: ATE = 283 mg/kg bw’ |

‘606-047-00-9 | 2-benzyl-2-dimethylamino-4'-morpholinobutyrophenone | 404-360-3 | 119313-12-1 |

Repr. 1B

Aquatic Acute 1

Aquatic Chronic 1

H360D

H400

H410

GHS08

GHS09

Dgr

H360D

H410’

‘607-232-00-7 |

pyridate (ISO);

O-(6-chloro-3-phenylpyridazin-4-yl) S-octyl thiocarbonate

259-686-7 | 55512-33-9 |

Acute Tox. 4

Skin Irrit. 2

Skin Sens. 1

Aquatic Acute 1

Aquatic Chronic 1

H302

H315

H317

H400

H410

GHS07

GHS09

Wng

H302

H315

H317

H410

oral: ATE = 500 mg/kg bw

M = 1

M = 10’

‘607-247-00-9 | dodecyl methacrylate | 205-570-6 | 142-90-5 | STOT SE 3 | H335 |

GHS07

Wng

H335 | | STOT SE 3; H335: C ≥ 10 %’ |

‘608-039-00-0 | 2-phenylhexanenitrile | 423-460-8 | 3508-98-3 |

Acute Tox. 4

Aquatic Chronic 2

H302

H411

GHS07

GHS09

Wng

H302

H411

oral:

ATE = 500 mg/kg bw’

‘613-054-00-0 |

thiabendazole (ISO);

2-(thiazol-4-yl)benzimidazole

205-725-8 | 148-79-8 | Aquatic Acute 1 Aquatic Chronic 1 |

H400

H410

GHS09

Wng

H410 | |

M = 1

M = 1’

‘616-018-00-2 | diethyltoluamide (ISO): N,N-diethyl-m-toluamide; [deet] | 205-149-7 | 134-62-3 |

Acute Tox. 4

Skin Irrit. 2

Eye Irrit. 2

H302

H315

H319

GHS07

Wng

H302

H315

H319

oral:

ATE = 1892 mg/kg bw’

(c)

the following rows are inserted:

Index No | Chemical Name | EC No | CAS No | Classification | Labelling | Specific Conc. Limits, M-factors and ATEs | Notes

Hazard Class and Category Code(s) | Hazard statement Code(s) | Pictogram, Signal Word Code(s) | Hazard statement Code(s) | Suppl. Hazard statement Code(s)

‘022-006-00-2 |

titanium dioxide;

[in powder form containing 1 % or more of particles with aerodynamic diameter ≤ 10 μm]

236-675-5 | 13463-67-7 | Carc. 2 | H351 (inhalation) |

GHS08

Wng

H351 (inhalation) | | | V, W, 10’

080-012-00-0 | methylmercuric chloride | 204-064-2 | 115-09-3 |

Carc. 2

Repr. 1A

Lact.

Acute Tox. 2

Acute Tox. 2

Acute Tox. 2

STOT RE 1

Aquatic Acute 1

Aquatic Chronic 1

H351

H360Df

H362

H330

H310

H300

H372 (nervous system, kidneys)

H400

H410

GHS08

GHS06

GHS09

Dgr

H351

H360Df

H362

H330

H310

H300

H372 (nervous system, kidneys)

H410

inhalation: ATE = 0,05 mg/l (dusts or mists)

dermal: ATE = 50 mg/kg bw

oral: ATE = 5 mg/kg bw

1

‘601-090-00-X | benzo[rst]pentaphene | 205-877-5 | 189-55-9 |

Carc. 1B

Muta. 2

H350

H341

GHS08

Dgr

H350

H341’

‘601-091-00-5 |

dibenzo[b,def]chrysene;

dibenzo[a,h]pyrene

205-878-0 | 189-64-0 |

Carc. 1B

Muta. 2

H350

H341

GHS08

Dgr

H350

H341’

‘603-236-00-8 | ethanol, 2,2’-iminobis-, N-(C13-15-branched and linear alkyl) derivs. | 308-208-6 | 97925-95-6 | Repr. 1B | H360D |

GHS08

Dgr

H360D’ | | |

‘607-733-00-0 |

cyflumetofen (ISO);

2-methoxyethyl (RS)-2-(4-tert-butylphenyl)-2-cyano-3-oxo-3-(α,α,α-trifluoro-o-tolyl)propionate

–

| 400882-07-7 |

Carc. 2

Skin Sens. 1A

H351

H317

GHS08

GHS07

Wng

H351

H317’

‘607-734-00-6 | pentapotassium 2,2’,2’’,2’’’,2’’’’-(ethane-1,2-diylnitrilo)pentaacetate | 404-290-3 | 7216-95-7 |

Acute Tox. 4 STOT RE 2

Eye Irrit. 2

H332

H373 (inhalation)

H319

GHS08

GHS07

Dgr

H332

H373 (inhalation)

H319

inhalation:

ATE = 1,5 mg/l (dusts or mists)’

‘607-735-00-1 | N-carboxymethyliminobis(ethylenenitrilo)tetra(acetic acid) | 200-652-8 | 67-43-6 |

Acute Tox. 4 STOT RE 2

Eye Irrit. 2

H332

H373 (inhalation)

H319

GHS08

GHS07

Dgr

H332

H373 (inhalation)

H319

inhalation:

ATE = 1,5 mg/l (dusts or mists)’

‘607-736-00-7 | pentasodium (carboxylatomethyl)iminobis(ethylenenitrilo)tetraacetate | 205-391-3 | 140-01-2 |

Acute Tox. 4

STOT RE 2

H332

H373 (inhalation)

GHS08

GHS07

Dgr

H332

H373 (inhalation)

inhalation:

ATE = 1,5 mg/l (dusts or mists)’

‘607-737-00-2 | diisohexyl phthalate | 276-090-2 | 71850-09-4 | Repr. 1B | H360FD |

GHS08

Dgr

H360FD’ | | |

‘608-069-00-4 | fludioxonil (ISO); 4-(2,2-difluoro-1,3-benzodioxol-4-yl)-1H-pyrrole-3-carbonitrile | — | 131341-86-1 |

Aquatic Acute 1

Aquatic Chronic 1

H400

H410

GHS09

Wng

H410 | |

M = 1

M = 10’

‘613-329-00-5 |

halosulfuron-methyl (ISO);

methyl 3-chloro-5-{[(4,6-dimethoxypyrimidin-2-yl)carbamoyl]sulfamoyl}-1-methyl-1H-pyrazole-4-carboxylate

–

| 100784-20-1 |

Repr. 1B

Aquatic Acute 1

Aquatic Chronic 1

H360D

H400

H410

GHS08

GHS09

Dgr

H360D

H410

M = 1000

M = 1000’

613-330-00-0 | 2-methylimidazole | 211-765-7 | 693-98-1 | Repr. 1B | H360Df |

GHS08

Dgr

H360Df | | |

‘616-225-00-8 | (RS)-2-methoxy-N-methyl-2-[α-(2,5-xylyloxy)-o-tolyl]acetamide; mandestrobin | — | 173662-97-0 | Aquatic Acute 1 Aquatic Chronic 1 |

H400

H410

GHS09

Wng

H410 | |

M = 1

M = 10’

‘616-226-00-3 |

carboxin (ISO);

2-methyl-N-phenyl-5,6-dihydro-1,4-oxathiine-3-carboxamide; 5,6-dihydro-2-methyl-1,4-oxathiine-3-carboxanilide

226-031-1 | 5234-68-4 |

STOT RE 2

Skin Sens. 1

Aquatic Acute 1

Aquatic Chronic 1

H373 (kidneys)

H317

H400

H410

GHS08

GHS07

GHS09

Wng

H373 (kidneys)

H317

H410

M = 1

M = 1’

‘616-227-00-9 |

metaflumizone (ISO); (EZ)-2’-[2-(4-cyanophenyl)-1-(α,α,α -trifluoro-m-tolyl)ethylidene]-[4-(trifluoromethoxy)phenyl]carbanilohydrazide [E-isomer ≥ 90 %, Z-isomer ≤ 10 % relative content]; [1]

(E)-2’-[2-(4-cyanophenyl)-1-(α,α,α -trifluoro-m-tolyl)ethylidene]-[4-(trifluoromethoxy)phenyl]carbanilohydrazide [2]

–

|

139968-49-3 [1]

852403-68-0 [2]

Repr. 2

Lact.

STOT RE 2

H361fd

H362

H373

GHS08

Wng

H361fd

H362

H373’

‘650-056-00-0 | dibutylbis(pentane-2,4-dionato-O,O’)tin | 245-152-0 | 22673-19-4 |

Repr. 1B

STOT RE 1

H360FD

H372 (immune system)

GHS08

Dgr

H360FD

H372 (immune system)’.